JP2002513291A - 神経上皮幹細胞及び系譜限定中間前駆体の産生、特性決定及び単離 - Google Patents
神経上皮幹細胞及び系譜限定中間前駆体の産生、特性決定及び単離Info
- Publication number
- JP2002513291A JP2002513291A JP54858198A JP54858198A JP2002513291A JP 2002513291 A JP2002513291 A JP 2002513291A JP 54858198 A JP54858198 A JP 54858198A JP 54858198 A JP54858198 A JP 54858198A JP 2002513291 A JP2002513291 A JP 2002513291A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- stem cells
- cns
- nep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 233
- 239000002243 precursor Substances 0.000 title claims abstract description 112
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 238000002955 isolation Methods 0.000 title claims description 11
- 238000012512 characterization method Methods 0.000 title description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 701
- 238000000034 method Methods 0.000 claims abstract description 144
- 210000002569 neuron Anatomy 0.000 claims abstract description 104
- 210000000933 neural crest Anatomy 0.000 claims abstract description 78
- 230000004069 differentiation Effects 0.000 claims abstract description 72
- 210000001428 peripheral nervous system Anatomy 0.000 claims abstract description 41
- 230000001537 neural effect Effects 0.000 claims abstract description 37
- 230000001939 inductive effect Effects 0.000 claims abstract description 23
- 239000003226 mitogen Substances 0.000 claims abstract description 21
- 239000001963 growth medium Substances 0.000 claims abstract description 20
- 238000000338 in vitro Methods 0.000 claims abstract description 19
- 238000012258 culturing Methods 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 210000004498 neuroglial cell Anatomy 0.000 claims description 68
- 210000000276 neural tube Anatomy 0.000 claims description 63
- 239000002609 medium Substances 0.000 claims description 60
- 230000002518 glial effect Effects 0.000 claims description 52
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 44
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 43
- 210000001161 mammalian embryo Anatomy 0.000 claims description 35
- 108010067306 Fibronectins Proteins 0.000 claims description 31
- 102000004243 Tubulin Human genes 0.000 claims description 31
- 108090000704 Tubulin Proteins 0.000 claims description 31
- 230000035755 proliferation Effects 0.000 claims description 31
- 241000287828 Gallus gallus Species 0.000 claims description 26
- 230000012010 growth Effects 0.000 claims description 26
- 210000002161 motor neuron Anatomy 0.000 claims description 25
- 102000008730 Nestin Human genes 0.000 claims description 23
- 108010088225 Nestin Proteins 0.000 claims description 23
- 210000005055 nestin Anatomy 0.000 claims description 23
- 230000024245 cell differentiation Effects 0.000 claims description 20
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 18
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 18
- 210000002257 embryonic structure Anatomy 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 17
- 101150022753 galc gene Proteins 0.000 claims description 17
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 16
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 16
- 230000001464 adherent effect Effects 0.000 claims description 16
- 238000004115 adherent culture Methods 0.000 claims description 15
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 15
- 239000000758 substrate Substances 0.000 claims description 14
- 230000013020 embryo development Effects 0.000 claims description 13
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 241000283690 Bos taurus Species 0.000 claims description 7
- 241000282472 Canis lupus familiaris Species 0.000 claims description 7
- 241000283086 Equidae Species 0.000 claims description 7
- 241000282326 Felis catus Species 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- 238000010899 nucleation Methods 0.000 claims description 7
- 241001494479 Pecora Species 0.000 claims description 6
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 5
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 5
- 241000282887 Suidae Species 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 4
- 239000008393 encapsulating agent Substances 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 3
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 3
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 3
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 210000003061 neural cell Anatomy 0.000 claims description 3
- 206010054949 Metaplasia Diseases 0.000 claims description 2
- ZIBSSYPUGNXJFJ-UHFFFAOYSA-N coronene-1-carbaldehyde Chemical compound C1=C2C(C=O)=CC3=CC=C(C=C4)C5=C3C2=C2C3=C5C4=CC=C3C=CC2=C1 ZIBSSYPUGNXJFJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000015689 metaplastic ossification Effects 0.000 claims description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims 5
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 210000004248 oligodendroglia Anatomy 0.000 abstract description 82
- 210000001130 astrocyte Anatomy 0.000 abstract description 80
- 238000011536 re-plating Methods 0.000 abstract description 6
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 description 246
- 210000003169 central nervous system Anatomy 0.000 description 100
- 230000014509 gene expression Effects 0.000 description 85
- 102100036123 Far upstream element-binding protein 2 Human genes 0.000 description 68
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 68
- 108091008794 FGF receptors Proteins 0.000 description 63
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 59
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 53
- 238000011161 development Methods 0.000 description 48
- 230000018109 developmental process Effects 0.000 description 48
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 46
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 45
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 45
- 241000700159 Rattus Species 0.000 description 41
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 40
- 102000005962 receptors Human genes 0.000 description 35
- 108020003175 receptors Proteins 0.000 description 35
- 238000002474 experimental method Methods 0.000 description 34
- 210000000278 spinal cord Anatomy 0.000 description 34
- 102100037362 Fibronectin Human genes 0.000 description 30
- 108010029485 Protein Isoforms Proteins 0.000 description 27
- 102000001708 Protein Isoforms Human genes 0.000 description 27
- 230000000694 effects Effects 0.000 description 24
- 210000001982 neural crest cell Anatomy 0.000 description 21
- 235000013330 chicken meat Nutrition 0.000 description 20
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 19
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 239000000427 antigen Substances 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 17
- 235000021186 dishes Nutrition 0.000 description 17
- 239000003550 marker Substances 0.000 description 17
- 230000004083 survival effect Effects 0.000 description 17
- 101150021185 FGF gene Proteins 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 16
- 210000004116 schwann cell Anatomy 0.000 description 14
- 239000003102 growth factor Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000002378 acidificating effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000001054 cortical effect Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 238000002372 labelling Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 10
- 241000271566 Aves Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000000461 neuroepithelial cell Anatomy 0.000 description 10
- 210000002460 smooth muscle Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 9
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 9
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 9
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 9
- 102400001175 Unique cartilage matrix-associated protein C-terminal fragment Human genes 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000027455 binding Effects 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 8
- 230000004186 co-expression Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000001301 EGF receptor Human genes 0.000 description 7
- 101800003838 Epidermal growth factor Proteins 0.000 description 7
- 101000577540 Homo sapiens Neuropilin-1 Proteins 0.000 description 7
- 101000974015 Homo sapiens Nucleosome assembly protein 1-like 1 Proteins 0.000 description 7
- 101000992283 Homo sapiens Optineurin Proteins 0.000 description 7
- 102100028762 Neuropilin-1 Human genes 0.000 description 7
- 241000283984 Rodentia Species 0.000 description 7
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 7
- 230000032823 cell division Effects 0.000 description 7
- 229940116977 epidermal growth factor Drugs 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 7
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 6
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 description 6
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 6
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000003365 immunocytochemistry Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000011278 mitosis Effects 0.000 description 6
- 229940053128 nerve growth factor Drugs 0.000 description 6
- 210000000653 nervous system Anatomy 0.000 description 6
- 230000004766 neurogenesis Effects 0.000 description 6
- 230000004031 neuronal differentiation Effects 0.000 description 6
- 210000001778 pluripotent stem cell Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 229930002330 retinoic acid Natural products 0.000 description 6
- 229960001727 tretinoin Drugs 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 5
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 5
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 5
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 5
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 5
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 5
- 210000003981 ectoderm Anatomy 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 238000004091 panning Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 108091008604 NGF receptors Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 4
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 210000000133 brain stem Anatomy 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 4
- 235000015220 hamburgers Nutrition 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 210000003757 neuroblast Anatomy 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 210000001328 optic nerve Anatomy 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000004590 Peripherins Human genes 0.000 description 3
- 108010003081 Peripherins Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004720 cerebrum Anatomy 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 210000001020 neural plate Anatomy 0.000 description 3
- 210000005155 neural progenitor cell Anatomy 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 230000014511 neuron projection development Effects 0.000 description 3
- 102000045246 noggin Human genes 0.000 description 3
- 108700007229 noggin Proteins 0.000 description 3
- 210000005047 peripherin Anatomy 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241000483002 Euproctis similis Species 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 241000611306 Taeniopygia guttata Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- XDFCIPNJCBUZJN-UHFFFAOYSA-N barium(2+) Chemical compound [Ba+2] XDFCIPNJCBUZJN-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 238000011509 clonal analysis Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000005216 enteric neuron Anatomy 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000001259 mesencephalon Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 230000023105 myelination Effects 0.000 description 2
- 210000004457 myocytus nodalis Anatomy 0.000 description 2
- 101150006061 neur gene Proteins 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000002856 peripheral neuron Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000002023 somite Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- 240000005369 Alstonia scholaris Species 0.000 description 1
- 241000269332 Ambystoma mexicanum Species 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 108010027344 Basic Helix-Loop-Helix Transcription Factors Proteins 0.000 description 1
- 102000018720 Basic Helix-Loop-Helix Transcription Factors Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 101710134292 Dorsalin-1 Proteins 0.000 description 1
- 101000588316 Doryteuthis pealeii 60 kDa neurofilament protein Proteins 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 1
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108700005084 Multigene Family Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101100163882 Mus musculus Ascl1 gene Proteins 0.000 description 1
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 description 1
- 101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 1
- 101000648554 Mus musculus Sushi domain-containing protein 6 Proteins 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- RHEXWAQFMZCXIM-UHFFFAOYSA-N NC(N)=N.N=C=S.OC1=CC=CC=C1.ClC(Cl)Cl Chemical compound NC(N)=N.N=C=S.OC1=CC=CC=C1.ClC(Cl)Cl RHEXWAQFMZCXIM-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101000993333 Rattus norvegicus Ciliary neurotrophic factor Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 244000156473 Vallaris heynei Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 101150030721 ata gene Proteins 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- JRXXLCKWQFKACW-UHFFFAOYSA-N biphenylacetylene Chemical compound C1=CC=CC=C1C#CC1=CC=CC=C1 JRXXLCKWQFKACW-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 210000002165 glioblast Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009546 growth abnormality Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 108010028309 kalinin Proteins 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 101150085091 lat-2 gene Proteins 0.000 description 1
- 108010046018 leukocyte inhibitory factor Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical compound O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001587 telencephalon Anatomy 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000010246 ultrastructural analysis Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000008189 vertebrate development Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0661—Smooth muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/08—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/852,744 US6361996B1 (en) | 1997-05-07 | 1997-05-07 | Neuroepithelial stem cells and glial-restricted intermediate precursors |
| US09/073,881 | 1998-05-06 | ||
| US08/852,744 | 1998-05-06 | ||
| US09/073,881 US6830927B2 (en) | 1997-05-07 | 1998-05-06 | Common neural progenitor for the CNS and PNS |
| PCT/US1998/009630 WO1998050526A1 (en) | 1997-05-07 | 1998-05-07 | Generation, characterization, and isolation of neuroepithelial stem cells and lineage restricted intermediate precursor |
| US10/025,333 US7037720B2 (en) | 1997-05-07 | 2001-12-19 | Neuroepithelial stem cells and glial-restricted intermediate precursors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002513291A true JP2002513291A (ja) | 2002-05-08 |
| JP2002513291A5 JP2002513291A5 (https=) | 2005-12-02 |
Family
ID=37057261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54858198A Ceased JP2002513291A (ja) | 1997-05-07 | 1998-05-07 | 神経上皮幹細胞及び系譜限定中間前駆体の産生、特性決定及び単離 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US6361996B1 (https=) |
| EP (1) | EP0983344A4 (https=) |
| JP (1) | JP2002513291A (https=) |
| AU (1) | AU751581C (https=) |
| CA (1) | CA2289021C (https=) |
| IL (1) | IL132584A0 (https=) |
| WO (1) | WO1998050526A1 (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263402B1 (en) * | 1998-10-19 | 2012-09-11 | Cornell Research Foundation, Inc. | Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells |
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US20050042749A1 (en) | 2001-05-16 | 2005-02-24 | Carpenter Melissa K. | Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease |
| JP5943533B2 (ja) | 2000-05-17 | 2016-07-06 | アステリアス バイオセラピューティクス インコーポレイテッド | 神経前駆細胞の集団 |
| US7250294B2 (en) | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
| US6897061B1 (en) * | 2000-06-16 | 2005-05-24 | Spinal Cord Society | Transdifferentiation of glial cells |
| AU2003211063A1 (en) | 2002-02-15 | 2003-09-09 | Cornell Research Foundation, Inc. | Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells |
| US7207743B2 (en) * | 2002-05-28 | 2007-04-24 | Polivka Parking Solutions Llc | Method and apparatus for constructing an automotive vehicle parking lot |
| US20050101014A1 (en) | 2002-07-11 | 2005-05-12 | Keirstead Hans S. | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| AR046076A1 (es) * | 2003-07-18 | 2005-11-23 | Otsuka Pharma Co Ltd | Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida |
| US20050153446A1 (en) * | 2003-11-07 | 2005-07-14 | Steindler Dennis A. | Culturing and differentiating neural precursor cells |
| EP1713513B1 (en) | 2004-01-16 | 2014-06-04 | Carnegie Mellon University | Cellular labeling for nuclear magnetic resonance techniques |
| CA2569978C (en) * | 2004-06-09 | 2017-06-06 | The University Court Of The University Of Edinburgh | Neural stem cells |
| AU2006207618A1 (en) * | 2005-01-19 | 2006-07-27 | Fidia Advanced Biopolymers S.R.L | Hyaluronic acid derivative and neural stem cells for SCI and PNT regeneration |
| US7803364B2 (en) | 2005-11-17 | 2010-09-28 | The Cleveland Clinic Foundation | Multipotent neural stem cells |
| JP2009533061A (ja) * | 2006-04-14 | 2009-09-17 | セルセンス， インコーポレイテッド | 細胞の標識を評価する方法 |
| EP2010646A2 (en) * | 2006-04-14 | 2009-01-07 | Carnegie Mellon University | Cellular labeling and quantification for nuclear magnetic resonance techniques |
| EP2617428A1 (en) | 2006-08-15 | 2013-07-24 | Agency for Science, Technology and Research | Mesenchymal stem cell conditioned medium |
| EP2099869B1 (en) | 2006-10-31 | 2013-05-01 | Sensient Colors Inc. | Modified pigments and methods for making and using the same |
| US20100119493A1 (en) * | 2007-04-17 | 2010-05-13 | University Of Rochester | Telencephalic Glial-Restricted Cell Populations and Related Compositions and Methods |
| JP5645658B2 (ja) * | 2007-07-10 | 2014-12-24 | カーネギー メロン ユニバーシティー | 核磁気共鳴技術のための細胞標識を製造するための組成物及び方法 |
| EP2201072B1 (en) | 2007-08-23 | 2018-11-14 | Sensient Colors LLC | Self-dispersed pigments and methods for making and using the same |
| CA2714010C (en) | 2008-01-30 | 2020-06-16 | Corning Incorporated | Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells |
| SG188918A1 (https=) | 2008-03-17 | 2013-04-30 | Agency Science Tech & Res | |
| AU2009241762B2 (en) * | 2008-05-02 | 2015-07-16 | Celsense Inc. | Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications |
| KR20110011658A (ko) | 2008-05-08 | 2011-02-08 | 유니버시티 오브 로체스터 | 최적화된 세포 제제에 의한 수초 질환의 치료 |
| US9688956B2 (en) | 2008-06-05 | 2017-06-27 | National Cheng Kung University | Method for preserving proliferation and differentiation potential of mesenchymal stem cells |
| US8669048B2 (en) | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| WO2010068946A1 (en) * | 2008-12-12 | 2010-06-17 | Nova Southeastern University | Methods of isolating and using stem cells |
| US20100158878A1 (en) | 2008-12-23 | 2010-06-24 | Alexandra Capela | Target populations of oligodendrocyte precursor cells and methods of making and using same |
| JP2012523479A (ja) | 2009-04-07 | 2012-10-04 | センシエント カラーズ エルエルシー | 自己分散性粒子並びにその製造方法及び使用方法 |
| SG178064A1 (en) | 2009-07-21 | 2012-03-29 | Abt Holding Co | Use of stem cells to reduce leukocyte extravasation |
| EP2456860B1 (en) | 2009-07-21 | 2018-09-05 | ABT Holding Company | Use of stem cells to reduce leukocyte extravasation |
| NZ602174A (en) * | 2010-02-05 | 2014-10-31 | Auckland Uniservices Ltd | Cell programming |
| WO2011106521A1 (en) | 2010-02-25 | 2011-09-01 | Abt Holding Company | Modulation of macrophage activation |
| EP2625264B1 (en) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| US8433419B2 (en) | 2010-10-13 | 2013-04-30 | Cardiac Pacemakers, Inc. | Method and apparatus for controlling neurostimulation according to physical state |
| EP2718416B1 (en) | 2011-06-06 | 2019-11-13 | Regenesys bvba | Expansion of stem cells in hollow fiber bioreactors |
| EP2954046B1 (en) | 2013-02-06 | 2025-10-15 | University Of Rochester | Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders |
| EP2970877B1 (en) | 2013-03-15 | 2018-07-25 | Wake Forest University Health Sciences | Neural progenitor cell differentiation |
| JP6666240B2 (ja) | 2013-04-12 | 2020-03-13 | フランチェスカ， サベリオ ラ | 移植のための臓器の改良 |
| DK2992088T3 (da) | 2013-04-30 | 2019-11-11 | Univ Leuven Kath | Celleterapi for myelodysplastiske syndromer |
| JP6633522B2 (ja) | 2013-11-16 | 2020-01-22 | テルモ ビーシーティー、インコーポレーテッド | バイオリアクターにおける細胞増殖 |
| US9724432B2 (en) | 2015-04-30 | 2017-08-08 | University Of Rochester | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder |
| US11406721B2 (en) | 2016-02-22 | 2022-08-09 | The Regents Of The University Of California | Compositions and methods for imaging cell populations |
| CN116121189A (zh) | 2016-03-30 | 2023-05-16 | 阿斯特利亚斯生物治疗股份公司 | 少突胶质细胞祖细胞组合物 |
| CA3052124C (en) * | 2017-01-31 | 2024-06-25 | Osaka University | Method for controlling differentiation of pluripotent stem cells |
| JP7457505B2 (ja) | 2017-05-10 | 2024-03-28 | ユニバーシティー オブ ロチェスター | 神経精神障害を処置する方法 |
| IL281628B2 (en) | 2018-09-19 | 2025-06-01 | Lineage Cell Therapeutics Inc | Methods for differentiating pluripotent stem cells in dynamic suspension culture |
| WO2020154533A1 (en) | 2019-01-23 | 2020-07-30 | Asterias Biotherapeutics, Inc. | Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells |
| AU2020336302A1 (en) | 2019-08-23 | 2022-03-03 | Sana Biotechnology, Inc. | CD24 expressing cells and uses thereof |
| MX2022011831A (es) | 2020-03-25 | 2023-01-04 | Sana Biotechnology Inc | Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas. |
| IL300516A (en) | 2020-08-13 | 2023-04-01 | Sana Biotechnology Inc | Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds |
| AU2022283291A1 (en) | 2021-05-27 | 2023-11-02 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
| KR20240046319A (ko) | 2021-07-14 | 2024-04-08 | 사나 바이오테크놀로지, 인크. | 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현 |
| JP2024535677A (ja) | 2021-08-11 | 2024-10-02 | サナ バイオテクノロジー，インコーポレイテッド | 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞 |
| AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| TW202321435A (zh) | 2021-08-11 | 2023-06-01 | 美商薩那生物科技公司 | 用於改變低免疫原性細胞中之基因表現之可誘導系統 |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| WO2025054202A1 (en) | 2023-09-05 | 2025-03-13 | Sana Biotechnology, Inc. | Method of screening a sample comprising a transgene with a unique barcode |
| WO2025151838A1 (en) | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08500245A (ja) * | 1992-07-27 | 1996-01-16 | カリフォルニア インスティテュート オブ テクノロジー | 哺乳動物の多能性神経幹細胞 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411883A (en) * | 1989-12-26 | 1995-05-02 | Somatix Therapy Corporation | Proliferated neuron progenitor cell product and process |
| US5589376A (en) | 1992-07-27 | 1996-12-31 | California Institute Of Technology | Mammalian neural crest stem cells |
| US5753506A (en) * | 1996-05-23 | 1998-05-19 | Cns Stem Cell Technology, Inc. | Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals |
-
1997
- 1997-05-07 US US08/852,744 patent/US6361996B1/en not_active Expired - Lifetime
-
1998
- 1998-05-06 US US09/073,881 patent/US6830927B2/en not_active Expired - Fee Related
- 1998-05-07 AU AU74811/98A patent/AU751581C/en not_active Ceased
- 1998-05-07 JP JP54858198A patent/JP2002513291A/ja not_active Ceased
- 1998-05-07 EP EP98922212A patent/EP0983344A4/en not_active Withdrawn
- 1998-05-07 WO PCT/US1998/009630 patent/WO1998050526A1/en not_active Ceased
- 1998-05-07 IL IL13258498A patent/IL132584A0/xx not_active IP Right Cessation
- 1998-05-07 CA CA2289021A patent/CA2289021C/en not_active Expired - Fee Related
-
2001
- 2001-12-19 US US10/025,333 patent/US7037720B2/en not_active Expired - Fee Related
-
2006
- 2006-05-01 US US11/415,056 patent/US7595194B2/en not_active Expired - Fee Related
-
2009
- 2009-09-28 US US12/568,419 patent/US20100015702A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08500245A (ja) * | 1992-07-27 | 1996-01-16 | カリフォルニア インスティテュート オブ テクノロジー | 哺乳動物の多能性神経幹細胞 |
Non-Patent Citations (17)
| Title |
|---|
| JPN4007016138, Ｓｏｃｉｅｔｙ ｆｏｒ Ｎｅｕｒｏｓｃｉｅｎｃｅ，１９９６，Ｖｏｌ．２２，ｐ．５２７，２１５．１２ * |
| JPN4007016139, Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｎｅｕｒｏｓｃｉｅｎｃｅ，１９９５，Ｖｏｌ．１５，Ｎｏ．５，ｐ．３６５３−３６６１ * |
| JPN4007016140, Ｇｅｎｅｓ ＆ Ｄｅｖｅｌｏｐｍｅｎｔ，１９９６，Ｖｏｌ．１０，Ｎｏ．２４，ｐ．３１２９−３１４０ * |
| JPN4007016480, Ｄｅｖｅｌｏｐｍｅｎｔａｌ Ｂｉｏｌｏｇｙ，１９９８，Ｖｏｌ．２００，ｐ．１−１５ * |
| JPN6008050264, Ｓｏｃｉｅｔｙ ｆｏｒ Ｎｅｕｒｏｓｃｉｅｎｃｅ，１９９６，Ｖｏｌ．２２，ｐ．５２７，２１５．１２ * |
| JPN6008050266, Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｎｅｕｒｏｓｃｉｅｎｃｅ，１９９５，Ｖｏｌ．１５，Ｎｏ．５，ｐ．３６５３−３６６１ * |
| JPN6008050269, Ｇｅｎｅｓ ＆ Ｄｅｖｅｌｏｐｍｅｎｔ，１９９６，Ｖｏｌ．１０，Ｎｏ．２４，ｐ．３１２９−３１４０ * |
| JPN6008050271, Ｊｏｕｒｎａｌ ｏｆ Ｎｅｕｒｏｃｙｔｏｌｏｇｙ，１９９２，Ｖｏｌ．２１，Ｎｏ．９，ｐ．６３５−６４７ * |
| JPN6008050273, Ｄｅｖｅｌｏｐｍｅｎｔａｌ Ｂｉｏｌｏｇｙ，１９９８，Ｖｏｌ．２００，ｐ．１−１５ * |
| JPN6008050275, Ｄｅｖｅｌｏｐｍｅｎｔａｌ Ｂｉｏｌｏｇｙ，１９９７，Ｖｏｌ．１８８，ｐ．４８−６３ * |
| JPN6009049890, Ｄｅｖｅｌｏｐｍｅｎｔａｌ Ｂｉｏｌｏｇｙ，１９９２，Ｖｏｌ．１５２，ｐ．３６３−３７２ * |
| JPN6009049892, Ｃｅｌｌ Ｂｉｏｌｏｇｙ，１９９２，Ｖｏｌ．３，ｐ．４１３−４２２ * |
| JPN6009049894, Ｎｅｕｒｏｎ，１９９０，Ｖｏｌ．５，ｐ．６１５−６２５ * |
| JPN6009049895, Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｎｅｕｒｏｓｃｉｅｎｃｅ，１９９２，Ｖｏｌ．１２，Ｎｏ．７，ｐ．２７５１−２７６４ * |
| JPN6009049898, Ｄｅｖｅｌｐｏｍｅｎｔａｌ Ｂｒａｉｎ Ｒｅｓｅａｒｃｈ，１９９０，Ｖｏｌ．５４，ｐ．２３５−２４８ * |
| JPN6009049899, Ｎｅｕｒｏｓｃｉｅｎｃｅ Ｌｅｔｔｅｒｓ，１９９３，Ｖｏｌ．１６３，ｐ．２２７−２３０ * |
| JPN6009049901, ＧＬＩＡ，１９９６，Ｖｏｌ．１６，ｐ．２７−３９ * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2289021A1 (en) | 1998-11-12 |
| AU751581B2 (en) | 2002-08-22 |
| EP0983344A1 (en) | 2000-03-08 |
| AU751581C (en) | 2003-06-19 |
| US7595194B2 (en) | 2009-09-29 |
| IL132584A0 (en) | 2001-03-19 |
| EP0983344A4 (en) | 2000-09-27 |
| US20020142460A1 (en) | 2002-10-03 |
| US6361996B1 (en) | 2002-03-26 |
| US7037720B2 (en) | 2006-05-02 |
| US20100015702A1 (en) | 2010-01-21 |
| US20060199264A1 (en) | 2006-09-07 |
| US6830927B2 (en) | 2004-12-14 |
| AU7481198A (en) | 1998-11-27 |
| US20020045251A1 (en) | 2002-04-18 |
| WO1998050526A1 (en) | 1998-11-12 |
| CA2289021C (en) | 2013-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002513291A (ja) | 神経上皮幹細胞及び系譜限定中間前駆体の産生、特性決定及び単離 | |
| JP4371179B2 (ja) | 系列限定ニューロン前駆体 | |
| Kilpatrick et al. | Cloning and growth of multipotential neural precursors: requirements for proliferation and differentiation | |
| US6949380B1 (en) | Transdifferentiation of epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells | |
| Izrael et al. | Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo | |
| Rao et al. | Immortalization and controlled in vitro differentiation of murine multipotent neural crest stem cells | |
| US20130017179A1 (en) | Lineage-Restricted Neuronal Precursors | |
| JPH10509319A (ja) | ドーパミン作動性細胞のインビトロ誘導 | |
| JP2002511246A (ja) | 系列特異性細胞および前駆体細胞 | |
| WO2004007700A1 (ja) | 神経系細胞の製造方法 | |
| Zhang et al. | Increased myelinating capacity of embryonic stem cell derived oligodendrocyte precursors after treatment by interleukin-6/soluble interleukin-6 receptor fusion protein | |
| Donaldson et al. | Human amniotic fluid stem cells do not differentiate into dopamine neurons in vitro or after transplantation in vivo | |
| JP2007520207A (ja) | 胚性幹細胞由来のｇａｂａ作動性ニューロンのインビトロ生成および神経疾患の処置におけるその使用 | |
| Qu et al. | Bromodeoxyuridine increases multipotency of human bone marrow-derived stem cells | |
| Li et al. | Engraftable neural crest stem cells derived from cynomolgus monkey embryonic stem cells | |
| Lin et al. | New mouse oligodendrocyte precursor (mOP) cells for studies on oligodendrocyte maturation and function | |
| US7041507B1 (en) | Transdiffentiation of transfected epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells | |
| KR20040079669A (ko) | Ｎｕｒｒ1 과발현에 의한 도파민성 신경세포의 분화방법 | |
| AU2002309073B2 (en) | Generation, characterization, and isolation of neuroepithelial stem cells and lineage restricted intermediate precursor | |
| EP1179046B1 (en) | Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells | |
| AU765517B2 (en) | Lineage-restricted precursor cells isolated from mouse neural tube and mouse embryonic stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050509 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050509 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070821 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071016 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071126 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080221 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081007 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090107 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091216 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100201 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100108 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100222 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20100419 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100525 |